Table 6.
Medication pairs involved in risk X category drug interactions (to be avoided).
| Medication pairs | Number of D/Is | Effect of drug interaction |
|---|---|---|
| Azithromycin-silodosin | 1 | Increased serum concentration of silodosin |
| Domperidone-escitalopram | 2 | Enhanced QTc-prolonging effect |
| Domperidone-quetiapine | 2 | Enhanced QTc-prolonging effect |
| Escitalopram-quetiapine | 1 | Enhanced QTc-prolonging effect |
| Atorvastatin-silodosin | 2 | Increased serum concentration of silodosin |
| Clopidogrel-esomeprazole | 4 | Diminished antiplatelet effect of clopidogrel |
| Ciprofloxacin-domperidone | 1 | Enhanced QTc-prolonging effect |
| Domperidone-fluconazole | 1 | Increased serum concentration of domperidone |
| Nifedipine-phenytoin | 1 | Increased serum concentration of phenytoin |
| Prazosin-tamsulosin | 1 | Enhanced antihypertensive effect |
| Domperidone-granisetron | 1 | Enhanced QTc-prolonging effect |
| Escitalopram-flupentixol | 1 | Enhanced QTc-prolonging effect |
| Bambuterol-salmeterol | 1 | Enhanced adverse/toxic effects |
| Amitriptyline-salbutamol + ipratropium | 1 | Enhanced anticholinergic effect |